Ignalis MP 500 Tablet SR is a combination oral antidiabetic medication containing Metformin (500 mg), Pioglitazone (15 mg), and Sitagliptin (100 mg), formulated to improve glycemic control in patients with type 2 diabetes mellitus. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production and enhancing peripheral insulin sensitivity. Pioglitazone, a thiazolidinedione, improves insulin sensitivity in adipose tissue, muscle, and the liver by activating peroxisome proliferator-activated receptor gamma (PPAR-γ). Sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, increases incretin hormone levels, thereby enhancing glucose-dependent insulin secretion and suppressing glucagon release. The sustained-release formulation ensures gradual drug release, improving patient compliance and maintaining stable plasma concentrations. Ignalis MP 500 is indicated for use as an adjunct to diet and exercise to improve glycemic control in adults inadequately controlled on monotherapy or dual therapy. It should be used with caution in patients with renal or hepatic impairment and contraindicated in those with hypersensitivity to any component or conditions predisposing to lactic acidosis. Regular monitoring of blood glucose, renal function, and liver enzymes is recommended during therapy. This combination therapy offers a multifaceted approach to managing hyperglycemia by targeting different pathophysiological mechanisms of type 2 diabetes.